Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D
NCT07545759 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 6, 2026
- Completion date
- November 30, 2027
- Enrollment
- 531 (estimated)
- Sites
- 89
Conditions
As the registry lists them; a condition with its own page is linked.